July 14, 2003
AIDS Clinical Trials Unit
Purpose: to study the safety of increasing doses of protease inhibitor (PI) drugs based on Therapeutic Drug Monitoring.
Purpose: to examine the use of a lopinavir/ritonavir (a ritonavir-enhanced, second-generation protease inhibitor)-based regimen, a non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimen, and a nucleoside-sparing regimen as the first treatment of HIV-1 infection.
Purpose: to see and compare if it is better to change anti-HIV medications as soon as a viral load is 200 or wait until viral load is slightly higher. Changing medications at different viral load levels might matter in terms of 1) the immune system's ability to repair itself even if HIV viral load is not completely suppressed and 2) whether HIV is more or less likely to develop resistance if changes in medications are delayed.
Purpose: to see how levels of HIV in the blood compare to those in the cerebrospinal fluid (CSF) before and after treatment with potent antiretroviral therapy.
Want to find out about more studies at the ACTU? Visit our new website!
This article was provided by Seattle Treatment Education Project. It is a part of the publication STEP Ezine.